The appropriate cutoff gastric pH value for Helicobacter pylori eradication with bismuth‐based quadruple therapy
出版年份 2020 全文链接
标题
The appropriate cutoff gastric pH value for
Helicobacter pylori
eradication with bismuth‐based quadruple therapy
作者
关键词
-
出版物
HELICOBACTER
Volume -, Issue -, Pages -
出版商
Wiley
发表日期
2020-10-22
DOI
10.1111/hel.12768
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Systematic review with meta-analysis: the worldwide prevalence of Helicobacter pylori infection
- (2018) M. Zamani et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Interchangeable Use of Proton Pump Inhibitors Based on Relative Potency
- (2018) David Y. Graham et al. Clinical Gastroenterology and Hepatology
- Comparative study of Helicobacter pylori eradication rates of concomitant therapy vs modified quadruple therapy comprising proton-pump inhibitor, bismuth, amoxicillin, and metronidazole in Korea
- (2018) Jung Wan Choe et al. HELICOBACTER
- Fifth Chinese National Consensus Report on the management of Helicobacter pylori infection
- (2018) Wen Zhong Liu et al. HELICOBACTER
- Bismuth-containing quadruple therapy versus concomitant quadruple therapy as first-line treatment for Helicobacter Pylori infection in an area of high resistance to clarithromycin: A prospective, cross-sectional, comparative, open trial
- (2018) Fernando Macías-García et al. HELICOBACTER
- Global Prevalence of Helicobacter pylori Infection: Systematic Review and Meta-Analysis
- (2017) James K.Y. Hooi et al. GASTROENTEROLOGY
- Randomized Trial Comparing Esomeprazole and Rabeprazole in First-line Eradication Therapy for Helicobacter pylori Infection based on the Serum Levels of Pepsinogens
- (2017) Tadashi Shimoyama et al. INTERNAL MEDICINE
- Potent acid inhibition by vonoprazan in comparison with esomeprazole, with reference to CYP2C19 genotype
- (2016) T. Kagami et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Triple terapia 10 días con esomeprazol 40 mg/12 h vs. cuádruple concomitante sin bismuto como tratamiento de primera línea de la infección por Helicobacter pylori
- (2016) Ana Campillo et al. Gastroenterologia y Hepatologia
- The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults
- (2016) Carlo A. Fallone et al. GASTROENTEROLOGY
- Management ofHelicobacter pyloriinfection—the Maastricht V/Florence Consensus Report
- (2016) P Malfertheiner et al. GUT
- Role of bismuth in improvingHelicobacter pylorieradication with triple therapy
- (2016) Maria Pina Dore et al. GUT
- Antibiotic resistance and CYP2C19 polymorphisms affect the efficacy of concomitant therapies forHelicobacter pyloriinfection: an open-label, randomized, single-centre clinical trial
- (2016) Junbo Hong et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- http://www.jgld.ro/wp/archive/y2016/n2/a4/
- (2016) Journal of Gastrointestinal and Liver Diseases
- Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial
- (2016) Jyh-Ming Liou et al. LANCET
- Comparison of the effects of esomeprazole 40 mg, rabeprazole 20 mg, lansoprazole 30 mg, and pantoprazole 40 mg on intragastrıc pH in extensive metabolizer patients with gastroesophageal reflux disease
- (2016) Altay Celebi et al. Turkish Journal of Gastroenterology
- Colloidal bismuth subcitrate impedes proton entry intoHelicobacter pyloriand increases the efficacy of growth-dependent antibiotics
- (2015) E. A. Marcus et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Optimised empiric triple and concomitant therapy forHelicobacter pylorieradication in clinical practice: the OPTRICON study
- (2015) J. Molina-Infante et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Bismuth, lansoprazole, amoxicillin and metronidazole or clarithromycin as first-lineHelicobacter pyloritherapy
- (2015) Wei Zhang et al. GUT
- Sequential therapy for 10 days versus triple therapy for 14 days in the eradication ofHelicobacter pyloriin the community and hospital populations: a randomised trial
- (2015) Jyh-Ming Liou et al. GUT
- Kyoto global consensus report onHelicobacter pylorigastritis
- (2015) Kentaro Sugano et al. GUT
- Daytime intragastric acid control: post hoc analyses of esomeprazole 20 mg and over-the-counter proton-pump inhibitors
- (2015) Philip Katz et al. Therapeutic Advances in Gastroenterology
- Twice-daily dosing of esomeprazole effectively inhibits acid secretion in CYP2C19 rapid metabolisers compared with twice-daily omeprazole, rabeprazole or lansoprazole
- (2014) S. Sahara et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Triple Therapy with High-Dose Proton-Pump Inhibitor, Amoxicillin, and Doxycycline Is Useless forHelicobacter pyloriEradication: A Proof-of-Concept Study
- (2014) Nuno Almeida et al. HELICOBACTER
- Intra-gastric pH following single oral administrations of rabeprazole and esomeprazole: double-blind cross-over comparison
- (2014) Kenji Furuta et al. JOURNAL OF CLINICAL BIOCHEMISTRY AND NUTRITION
- Long-term pretreatment with proton pump inhibitor andHelicobacter pylorieradication rates
- (2014) Seung Bae Yoon WORLD JOURNAL OF GASTROENTEROLOGY
- Efficacy of tailoredHelicobacter pylorieradication therapy based on antibiotic susceptibility andCYP2C19genotype
- (2014) Mitsushige Sugimoto WORLD JOURNAL OF GASTROENTEROLOGY
- Efficacy of Bismuth-Containing Quadruple Therapies for Clarithromycin-, Metronidazole-, and Fluoroquinolone-Resistant Helicobacter pylori Infections in a Prospective Study
- (2013) Xiao Liang et al. Clinical Gastroenterology and Hepatology
- Effects of CYP2C19 Loss-of-Function Variants on the Eradication of H. pylori Infection in Patients Treated with Proton Pump Inhibitor-Based Triple Therapy Regimens: A Meta-Analysis of Randomized Clinical Trials
- (2013) Hui-Lin Tang et al. PLoS One
- High-dose, ten-day esomeprazole, amoxicillin and metronidazole triple therapy achieves high Helicobacter pylori eradication rates
- (2012) J. Sánchez-Delgado et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- A comparison of the acid-inhibitory effects of esomeprazole and rabeprazole in relation to pharmacokinetics and CYP2C19 polymorphism
- (2012) N. G. Hunfeld et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Meta-analysis: esomeprazole or rabeprazole vs. first-generation pump inhibitors in the treatment of Helicobacter pylori infection
- (2012) A. G. McNicholl et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Randomised clinical trial: twice daily esomeprazole 40 mg vs. pantoprazole 40 mg in Barrett’s oesophagus for 1 year
- (2011) N. de Bortoli et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial
- (2011) Peter Malfertheiner et al. LANCET
- The effects of dose and timing of esomeprazole administration on 24-h, daytime and night-time acid inhibition in healthy volunteers
- (2010) C. Wilder-Smith et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Effect of CYP2C19 Genetic Polymorphisms on the Efficacy of Proton Pump Inhibitor-Based Triple Therapy forHelicobacter pyloriEradication: A Meta-Analysis
- (2008) Fujun Zhao et al. HELICOBACTER
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now